We are dedicated to finding, developing, and commercializing new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.
Moleac’s first product, developed to address unmet needs in post-stroke and post-traumatic brain injury recovery. Over 45 scientific publications detail its pre-clinical and clinical pharmacology, as well as its efficacy and safety profile. Today, NeuroAiD is available in over 32 countries worldwide and benefits approximately to 35,000 patients each year.
We continue to invest in research to further expand the knowledge on NeuroAiD for Traumatic Brain Injury (TBI), Spinal Cord Injury and Cognitive Decline.